← Latest papers
⚗️ biochemistry

Selective binders of a cotranslational folding intermediate

This study demonstrates the feasibility of targeting transient, cotranslational folding intermediates by using mRNA display to identify cyclic peptides that selectively bind a cryptic pocket formed by a nascent polypeptide and ribosomal proteins, offering a novel strategy for drug discovery beyond mature protein targets.

Original authors: Prakash, O., Voisin, T. B., Roeselova, A., Jorgensen, C. M., Desmet, J. S., Nans, A., Davies, R., Walport, L. J., Balchin, D.

Published 2026-11-02
📖 5 min read🧠 Deep dive

Original authors: Prakash, O., Voisin, T. B., Roeselova, A., Jorgensen, C. M., Desmet, J. S., Nans, A., Davies, R., Walport, L. J., Balchin, D.

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

Most medicines work by finding a finished protein, the molecular machine that carries out a task in a cell, and sticking to it. This usually happens after the protein has been fully built and folded into its final shape. If a protein is misshapen or lacks a clear place for a drug to grab onto, it is often considered impossible to treat. For decades, scientists have accepted that once a protein is made, its structure is fixed, and if that structure hides the weak spots, the protein remains out of reach for new drugs. However, proteins do not appear fully formed. They are built one piece at a time, like a long rope being pulled through a narrow tunnel. During this construction process, the rope twists and turns into temporary shapes that exist only for a moment before the rest of the protein is added. These fleeting, half-finished states are usually invisible to the immune system and ignored by drug developers, yet they might hold the key to treating diseases that have long seemed untouchable.

A team of researchers at the Francis Crick Institute and Imperial College London has now shown that these temporary, half-built proteins contain hidden pockets that can be targeted with high precision. They focused on a large bacterial enzyme called beta-galactosidase, which is made of four identical parts that lock together to work. The scientists wanted to see if they could find a molecule that would stick to this enzyme only while it was being built, and not once it was finished. To do this, they created a library of millions of tiny, ring-shaped molecules, known as cyclic peptides, and used a method called mRNA display to test which ones would stick to a ribosome—the cellular machine that builds proteins—while it was in the middle of making beta-galactosidase. They specifically looked for molecules that would grab onto the enzyme when it was about halfway finished, a stage where the protein is still attached to the ribosome and has not yet folded into its final form.

The search was successful. The researchers identified three distinct ring-shaped peptides that latched onto the half-built enzyme with extreme tightness, binding so strongly that they stayed attached even when the concentration of the peptide was very low. Crucially, these same molecules showed almost no interest in the finished, fully folded enzyme. They also ignored the ribosome when it was building a different protein, proving that the binders were not just sticking to the construction machine itself, but were recognizing a specific combination of the half-built protein and the machine. This selectivity is vital because it means a drug could potentially target a disease-causing protein without interfering with thousands of other healthy proteins in the body.

To understand how these tiny rings managed to grab onto such a specific target, the team used advanced imaging techniques to look at the structure of the complex. They found that as the protein emerges from the ribosome, a short section of it folds into a tight spiral, or helix, right against the surface of the ribosome. This helix, together with two specific proteins on the ribosome's surface, creates a unique, temporary pocket that does not exist in the finished enzyme. The discovered peptides fit perfectly into this pocket, like a key sliding into a lock that only appears for a brief moment during construction. The researchers confirmed that this pocket is formed by the interaction between the new protein and the ribosome; without the ribosome, the pocket disappears, and without the specific folding of the new protein, the pocket does not form.

The study went further to test exactly what parts of the protein were necessary for this binding. They found that a very short stretch of the protein, consisting of just thirteen amino acids, was enough to create the binding site. Even when the rest of the protein was replaced with a completely different, unstructured sequence, the peptides still bound tightly as long as that short helical section was present and correctly folded. This suggests that the binding relies on a specific shape created by a small part of the protein, rather than the entire molecule. The researchers also showed that this binding happens in real-time during the synthesis of the protein, not just when the protein is artificially stopped. When they watched the protein being built in a test tube, the peptides attached themselves at the exact moment the critical section of the protein emerged from the ribosome.

This work provides a proof of concept that it is possible to target the intermediate stages of protein creation. The researchers demonstrated that these transient, half-folded states are not just fleeting moments of chaos, but stable structures with unique surfaces that can be exploited. By finding molecules that recognize these specific, temporary shapes, scientists can potentially develop a new class of drugs that stop disease-causing proteins before they ever finish being built. If a drug can bind to a protein while it is being made, it can trigger the cell's natural quality control systems to destroy the defective protein and the instructions for making it. While the current study was performed in a test tube and on bacterial proteins, the approach offers a new path forward for targeting difficult proteins in human cells, expanding the range of diseases that might one day be treated.

Drowning in papers in your field?

Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.

Try Digest →